Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (04) : 282-287     DOI: 10.3971/j.issn.1000-8578.2022.21.1117
Research Progress of Ferroptosis in Head and Neck Squamous Cell Carcinoma
XIE Zhanghong, HUA Qingquan
Department of Otolaryngology-head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China
Download: PDF(3535 KB)   ( 73 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Squamous cell carcinoma of the head and neck (HNSCC) is one of the cancers with the highest incidence rate in the world. Due to the presence of postoperative recurrence and resistance to some chemotherapeutics after the surgery, the prognosis of advanced HNSCC patients is not optimistic. Therefore, it is urgent to improve the efficiency of chemotherapeutics for HNSCC and the prognosis of HNSCC patients. Recent studies have found that ferroptosis has regulatory effect on the growth and proliferation of some types of tumor cells, reducing drug resistance in tumor treatment to a certain extent, and showing great potential in the prevention and treatment of tumors. Therefore, this article will summarize the anti-tumor mechanism of ferroptosis and the current research progress in HNSCC, providing new evidence for the treatment of HNSCC.
Keywords HNSCC      Ferroptosis      Chemotherapy      Oncotherapy     
ZTFLH:  R739.91  
Issue Date: 15 April 2022
 Cite this article:   
XIE Zhanghong,HUA Qingquan. Research Progress of Ferroptosis in Head and Neck Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 282-287.
E-mail this article
E-mail Alert
Articles by authors
XIE Zhanghong
HUA Qingquan
[1] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics
for the year 2020: An overview[J]. Int J Cancer, 2021, 149(4):
[2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):
[3] Kim YJ, Kim JH. Increasing incidence and improving survival of
oral tongue squamous cell carcinoma[J]. Sci Rep, 2020, 10(1): 7877.
[4] Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J].
CA Cancer J Clin, 2021, 71(1): 7-33.
[5] Lenze NR, Farquhar DR, Dorismond C, et al. Age and risk of
recurrence in oral tongue squamous cell carcinoma: Systematic
review[J]. Head Neck, 2020, 42(12): 3755-3768.
[6] Roh JL, Kim EH, Jang HJ, et al. Induction of ferroptotic cell death
for overcoming cisplatin resistance of head and neck cancer[J].
Cancer Lett, 2016, 381(1): 96-103.
[7] Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: An
Iron-Dependent Form of Nonapoptotic Cell Death[J]. Cell, 2012,
149(5): 1060-1072.
[8] Chen X, Li J, Kang R, et al. Ferroptosis: machinery and
regulation[J]. Atophagy, 2020, 17(9): 2054-2081.
[9] Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT
in cancer: ferroptosis, nutrient dependency, and cancer therapy[J].
Protein Cell, 2021, 12(8): 599-620.
[10] Chen X, Kang R, Kroemer G, et al. Broadening horizons: the role of
ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021, 18(5): 280-296.
[11] Tang D, Chen X, Kang R, et al. Ferroptosis: molecular
mechanisms and health implications[J]. Cell Res, 2021, 31(2):
[12] Chen X, Kang R, Kroemer G, et al. Targeting ferroptosis in
pancreatic cancer: a double-edged sword[J]. Trends Cancer, 2021,
7(10): 891-901.
[13] Sui X, Zhang R, Liu S, et al. RSL3 Drives Ferroptosis Through
GPX4 Inactivation and ROS Production in Colorectal Cancer[J].
Front Pharmacol, 2018, 9: 1371.
[14] Bogdan AR, Miyazawa M, Hashimoto K, et al. Regulators of
Iron Homeostasis: New Players in Metabolism, Cell Death, and
Disease[J]. Trends Biochem Sci, 2016, 41(3): 274-286.
[15] Yang WS, Stockwell BR. Ferroptosis: Death by Lipid
Peroxidation[J]. Trends Cell Biol, 2016, 26(3): 165-176.
[16] Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs
navigate cells to ferroptosis[J]. Nat Chem Biol, 2017, 13(1): 81-90.
[17] Chu B, Kon N, Chen D, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis
pathway[J]. Nat Cell Biol, 2019, 21(5): 579-591.
[18] Magtanong L, Ko PJ, To M, et al. Exogenous Monounsaturated
Fatty Acids Promote a Ferroptosis-Resistant Cell State[J]. Cell
Chem Biol, 2019, 26(3): 420-432. e9.
[19] Yan B, Ai Y, Sun Q, et al. Membrane Damage during Ferroptosis
Is Caused by Oxidation of Phospholipids Catalyzed by the
Oxidoreductases POR and CYB5R1[J]. Mol Cell, 2021, 81(2):
355-369. e10.
[20] Shimada K, Skouta R, Kaplan A, et al. Global survey of cell death
mechanisms reveals metabolic regulation of ferroptosis[J]. Nat
Chem Biol, 2016, 12(7): 497-503.
[21] Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase
FSP1 acts parallel to GPX4 to inhibit ferroptosis[J]. Nature, 2019,
575(7784): 688-692.
[22] Dai E, Meng L, Kang R, et al. ESCRT-Ⅲ-dependent membrane
repair blocks ferroptosis[J]. Biochem Biophys Res Commun,
2020, 522(2): 415-421.
[23] Kraft VAN, Bezjian CT, Pfeiffer S, et al. GTP Cyclohydrolase
1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid
Remodeling[J]. ACS Cent Sci, 2020, 6(1): 41-53.
[24] Li B, Yang L, Peng X, et al. Emerging mechanisms and
applications of ferroptosis in the treatment of resistant cancers[J].
Biomed Pharmacother, 2020, 130: 110710.
[25] Wang H, Liu C, Zhao Y, et al. Inhibition of LONP1 protects
against erastin-induced ferroptosis in Pancreatic ductal
adenocarcinoma PANC1 cells[J]. Biochem Biophys Res Commun,
2020, 522(4): 1063-1068.
[26] Zou Y, Palte MJ, Deik AA, et al. A GPX4-dependent cancer cell
state underlies the clear-cell morphology and confers sensitivity to
ferroptosis[J]. Nat Commun, 2019, 10(1): 1617.
[27] Yang WH, Chi JT. Hippo pathway effectors YAP/TAZ as novel
determinants of ferroptosis[J]. Mol Cell Oncol, 2020, 7(1):
[28] Müller S, Sindikubwabo F, Ca?eque T, et al. CD44 regulates
epigenetic plasticity by mediating iron endocytosis[J]. Nat Chem,
2020, 12(10): 929-938.
[29] Yu W, Chen Y, Putluri N, et al. Acquisition of Cisplatin Resistance
Shifts Head and Neck Squamous Cell Carcinoma Metabolism
toward Neutralization of Oxidative Stress[J]. Cancers(Basel),
2020, 12(6): 1670.
[30] Ma Z, Zhang H, Lian M, et al. SLC7A11, a component of
cysteine/glutamate transporter, is a novel biomarker for the
diagnosis and prognosis in laryngeal squamous cell carcinoma[J].
Oncol Rep, 2017, 38(5): 3019-3029.
[31] Hémon A, Louandre C, Lailler C, et al. SLC7A11 as a biomarker
and therapeutic target in HPV-positive head and neck Squamous
Cell Carcinoma[J]. Biochem Biophys Res Commun, 2020, 533(4):
[32] Yoshikawa M, Tsuchihashi K, Ishimoto T, et al. xCT Inhibition
Depletes CD44v-Expressing Tumor Cells That Are Resistant
to EGFR-Targeted Therapy in Head and Neck Squamous Cell
Carcinoma[J]. Cancer Res, 2013, 73(6): 1855-1866.
[33] Okazaki S, Shintani S, Hirata Y, et al. Synthetic lethality of the
ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione
deficiency-resistant cancer cells[J]. Oncotarget, 2018, 9(73):
[34] Otsuki Y, Yamasaki J, Suina K, et al. Vasodilator oxyfedrine
inhibits aldehyde metabolism and thereby sensitizes cancer cells
to xCT-targeted therapy[J]. Cancer Sci, 2020, 111(1): 127-136.
[35] Roh JL, Kim EH, Jang H, et al. Aspirin plus sorafenib potentiates
cisplatin cytotoxicity in resistant head and neck cancer cells
through xCT inhibition[J]. Free Radic Biol Med, 2017, 104: 1-9.
[36] Zhu T, Shi L, Yu C, et al. Ferroptosis Promotes Photodynamic
Therapy: Supramolecular Photosensitizer-Inducer Nanodrug
for Enhanced Cancer Treatment[J]. Theranostics, 2019, 9(11):
[37] Lin YH, Chiu V, Huang CY, et al. Promotion of Ferroptosis in Oral
Cancer Cell Lines by Chrysophanol[J]. Curr Top Nutraceutical
Res, 2019, 18(3): 273-276.
[38] Zhu S, Yu Q, Huo C, et al. Ferroptosis: A Novel Mechanism of
Artemisinin and its Derivatives in Cancer Therapy[J]. Curr Med
Chem, 2021, 28(2): 329-345.
[39] Lin R, Zhang Z, Chen L, et al. Dihydroartemisinin (DHA)
induces ferroptosis and causes cell cycle arrest in head and neck
carcinoma cells[J]. Cancer Lett, 2016, 381(1): 165-175.
[40] Shin D, Kim EH, Lee J, et al. Nrf2 inhibition reverses resistance
to GPX4 inhibitor-induced ferroptosis in head and neck cancer[J].
Free Radic Biol Med, 2018, 129: 454-462.
[41] Roh JL, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the
resistance of cisplatin-resistant head and neck cancer cells to
artesunate-induced ferroptosis[J]. Redox Biol, 2017, 11: 254-262.
[42] Raudenská M, Balvan J, Masa?ík M. Cell death in head and neck
cancer pathogenesis and treatment[J]. Cell Death Dis, 2021, 12(2): 192.
[43] Sun X, Ou Z, Xie M, et al. HSPB1 as a novel regulator of
ferroptotic cancer cell death[J]. Oncogene, 2015, 34(45):
[44] Mittler R, Darash-Yahana M, Sohn YS, et al. NEET Proteins: A
New Link Between Iron Metabolism, Reactive Oxygen Species,
and Cancer[J]. Antioxid Redox Signal, 2019, 30(8): 1083-1095.
[45] Lee J, You JH, Shin D, et al. Inhibition of Glutaredoxin 5
predisposes Cisplatin-resistant Head and Neck Cancer Cells to
Ferroptosis[J]. Theranostics, 2020, 10(17): 7775-7786.
[46] Kim EH, Shin D, Lee J, et al. CISD2 inhibition overcomes
resistance to sulfasalazine-induced ferroptotic cell death in head
and neck cancer[J]. Cancer Lett, 2018, 432: 180-190.
[47] Wang X, Liu K, Gong H, et al. Death by histone deacetylase
inhibitor quisinostat in tongue squamous cell carcinoma via
apoptosis, pyroptosis, and ferroptosis[J]. Toxicol Appl Pharmacol,
2021, 410: 115363.
[48] Miyazaki H, Takahashi RU, Prieto-Vila M, et al. CD44 exerts a
functional role during EMT induction in cisplatin-resistant head
and neck cancer cells[J]. Oncotarget, 2018, 9(11): 10029-10041.
[49] Ye J, Jiang X, Dong Z, et al. Low-Concentration PTX And
RSL3 Inhibits Tumor Cell Growth Synergistically By Inducing
Ferroptosis In Mutant p53 Hypopharyngeal Squamous
Carcinoma[J]. Cancer Manag Res, 2019, 11: 9783-9792.
[50] Han F, Li W, Chen T, et al. Ferroptosis-related genes for predicting
prognosis of patients with laryngeal squamous cell carcinoma[J].
Eur Arch Otorhinolaryngol, 2021, 278(8): 2919-2925.
[51] He F, Chen Z, Deng W, et al. Development and validation of a
novel ferroptosis-related gene signature for predicting prognosis
and immune microenvironment in head and neck squamous cell
carcinoma[J]. Int Immunopharmacol, 2021, 98: 107789.
[52] Tang Y, Li C, Zhang YJ, et al. Ferroptosis-Related Long Non-
Coding RNA signature predicts the prognosis of Head and neck
squamous cell carcinoma[J]. Int J Biol Sci, 2021, 17(3): 702-711.
Related articles from Frontiers Journals
[1] MAO Wanli, RAN Li, LI Jiehui, LI Fenghu, CHANG Jianying, MU Junyu, MEI Fan, HU Lili, DU Yanjun, TIAN Xue, QIN Yao, YIN Shuishui. Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 937-943.
[2] CHEN Zegang, WANG Yongbing, OU Tao. Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 982-986.
[3] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[4] WEI Zongjie, KUANG Youlin, CHEN Yong, WANG Lu, CHEN Xiao, GOU Xin. Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 698-702.
[5] FAN Bingjie, CHANG Yu, LIU Xiyang, ZHANG Mingzhi, ZHANG Lei. Effects of Chemoradiotherapy Versus Chemotherapy Alone on Survival of Patients with Primary Mediastinal Large B-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 205-212.
[6] LIU Zhenghao, YANG Chunguang, HU Zhiquan. Research Progress on Immunoregulation of Chemotherapeutic Agents[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 72-77.
[7] LU Mei, YANG Xiaojuan, ZOU Jieya, GUO Rong, WANG Xin, ZHANG Qian, DENG Xuepeng, TAO Jianfen, NIE Jianyun, YANG Zhuangqing. Efficacy Prediction Model for Neoadjuvant Chemotherapy on Breast Cancer Based on Differential Genes Expression[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1071-1077.
[8] SUN Chongyuan, ZHAO Dongbing. Characteristics and Risk Factors of Postoperative Complications in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1046-1052.
[9] ?WU Zhaoyang, WANG Shenglin, SHEN Rongkai, CHEN Fei, LIN Jianhua, ZHU Xia, ZHANG Zhenzhen. Association Between Osteogenic Differentiation in Soft Tissue Lump and Clinicopathological Characteristics of Osteosarcoma Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 859-863.
[10] HE Puyi, LI Xuemei, WANG Yunpeng, XU Bo, WANG Haiyun, ZHANG Jing, PU Weigao, CHEN Hao. Advances in Application of PDT Combined with Multiple Therapies on Unresectable Extrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 893-897.
[11] PAN Zhongmian, CHEN Qi, LI Li. Prognosis of Stage ⅠB-ⅡA Cervical Squamous Cell Carcinoma Patients with Intermediate Risk Factors Treated with Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy: A Prospective Randomized Controlled Trial[J]. Cancer Research on Prevention and Treatment, 2021, 48(07): 714-718.
[12] YANG Xiaoli, WANG Cailing, XIA Jin, WANG Junsheng. Clinical Efficacy of Anlotinib Combined with Paclitaxel and Cisplatin as First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(07): 719-722.
[13] KONG Tiandong, CHEN Lu, DUAN Fangfang, WANG Liuyan, ZHOU Hanli, ZHAO Xiaoli, LIU Mengmeng, LIU Danna. Relation Between CD8+T Lymphocyte Infiltration and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(05): 484-488.
[14] DAI Yuhong, TAN Ximin, LI Yiming, HUANG Tingting, QIU Hong, QIU Ping. Clinical Analysis of Oxaliplatin-related Thrombocytopenia in Patients with Digestive System Malignancy[J]. Cancer Research on Prevention and Treatment, 2021, 48(05): 497-502.
[15] ZHOU Yajuan, MOU Yanhua, HU Desheng. An Interpretation of CSCO/ASCO International Guideline of Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage Ⅱ-Ⅳa Nasopharyngeal Carcinoma in 2021[J]. Cancer Research on Prevention and Treatment, 2021, 48(05): 553-562.
Full text